India to tackle global obesity with cheap fat-loss jabs

India prepared to unleash low‑cost generic versions of injections like Ozempic after a key patent expired on Friday.

The move will dramatically widen access to treatments especially in middle-income countries, where soaring demand has collided with steep prices. By the end of 2026, core patents on semaglutide will have expired in 10 countries that represent 48 percent of the global obesity burden